Table 1.
Characteristics of the included studies.
| Reference | Patient age | Cases | Interventions | Treatment (weeks) | Patients | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Treatment group | Control group | |||||||||
| Regimes | Viral suppression rate | ΔCD4 from baseline (mean, SD/SE, range) | Regimens | Viral suppression rate | ΔCD4 from baseline (mean, SD/SE, range) | |||||
| Kozal et al. (2012) | ≥18 | 94 | RAL+ATV/r | 74.6% | 166 ± 133.9 | ATV/r+RTV+TDF/FTC | 63.3% | 127 ± 95.9 | 24 | ART-naive patients |
| Reynes et al. (2011) | ≥18 | 206 | RAL +LPV/r | 83.2% | 214.9 | LPV/r+TDF/FTC | 84.8% | 245 | 4 | ART-naive patients |
| Paton et al. (2014) | > 12 | 859 | RAL +LPV/r | 66.1% | 260.0 ± 185.5 | LPV/r+NRTIs | 65.0% | 234.0 ± 208.1 | 96 | ART-experienced patients |
| Amin et al. (2015) | ≥16 | 541 | RAL +LPV/r | 70.0% | 228.7 ± 184.6 | LPV/r+NRTIs | 67.5% | 201.7 ± 193.7 | 96 | ART-experienced patients |
| Group et al. (2013) | ≥16 | 541 | RAL +LPV/r | 71.1% | 167.4 ± 142.1 | LPV/r+NRTIs | 70.5% | 132.5 ± 146.0 | 48 | ART-experienced patients |
| La Rosa et al. (2016) | ≥18 | 515 | RAL +LPV/r | 82.3% | 199.0 ± 131.2 | LPV/r+NRTIs | 80.4% | 190.0 ± 133.6 | 48 | ART-experienced patients |
| Raffi et al. (2014) | ≥18 | 805 | RAL+DRV/r | 84.8% | 266(250-283) | DRV/r +TDF–FTC | 80.9% | 268(250-284) | 96 | ART-naive patients |
| Hakim et al. (2018) | > 12 | 859 | RAL +LPV/r | 72.0% | 296.0 ± 258.9 | LPV/r+NRTIs | 75.0% | 290.0 ± 247.6 | 24 | ART-experienced patients |
RAL, raltegravir; LPV/r, ritonavir-booted lopinavir; NRTI, nucleoside reverse transcriptase inhibitor; DRV/r, ritonavir-booted darunavir; ATV/r, ritonavir-booted atazanavir.